All Stories

  1. Mechanisms, Mediators, and Pharmacological Approaches Targeting Brain Cholesterol Transport in Alzheimer’s Disease
  2. Development, optimization and validation of an absolute specific assay for active myeloperoxidase (MPO) and its application in a clinical context: role of MPO specific activity in coronary artery disease
  3. Testing a Combination of Markers of Systemic Redox Status as a Possible Tool for the Diagnosis of Late Onset Alzheimer’s Disease
  4. TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress
  5. Monocyte count at onset predicts poststroke outcomes during a 90-day follow-up
  6. Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes
  7. Leptin/adiponectin ratio predicts poststroke neurological outcome
  8. serum paraoxonase in alzheimer and MCI
  9. Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis
  10. Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke
  11. TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis
  12. Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways
  13. N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis
  14. Balanced and unbalanced solutions modulate the release of Matrix Metalloproteinase-9 (MMP-9) from neutrophils in response to inflammatory stimuli: an in vitro study
  15. Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding
  16. Effects of two different strategies of fluid administration on inflammatory mediators, plasma electrolytes and acid/base disorders in patients undergoing major abdominal surgery: a randomized double blind study
  17. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
  18. Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms
  19. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry
  20. Timing of Serum Active MMP-9 and MMP-2 Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage
  21. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis